- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01733186
Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects
Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects: A Phase I/IIa Clinical Trial in Patients With Focal, Full-thickness Grade 3-4 Articular Cartilage Defects of the Knee
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Conventional treatment modalities have not been able to provide complete and sustained resolution of symptoms following damage to the articular cartilage. Despite the numerous techniques available today, complete healing of damaged or defective cartilage or consistent reproduction of normal hyaline cartilage does not occur, and continuous drug administration or secondary surgeries are common.
Research in mesenchymal stem cells has had a rapid acceleration over the past decade and MSC-based therapy has become one of the objects of investigation for a new branch of medicine termed regenerative medicine. This emerging technology shows great promise for producing transplantable cartilage constructs to restore the function of degenerated joints.
CARTISTEM®, a combination of human umbilical cord blood-derived mesenchymal stem cells and sodium hyaluronate, is intended to be used as a single-dose cellular therapeutic agent for cartilage regeneration in human subjects with cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Cartilage Restoration Center; RUSH University Medical Center
-
-
Massachusetts
-
Chestnut Hill, Massachusetts, United States, 02467
- Cartilage Repair Center; Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with an intended- to- treat single focal, full-thickness cartilage defect (ICRS [International Cartilage Repair Society] Grade 3 or 4) of the knee as a result of ageing, trauma, or degenerative diseases.
- Age ≥ 18 years old
- Size of the articular cartilage lesion is ≥ 2 cm2
- Swelling, tenderness and active range of motion ≤ Grade II
- Joint pain : 20-mm - 60-mm on VAS (Visual Analog Scale) at the time of Screening
- Appropriate blood coagulation, kidney and liver function laboratory parameters: PT(INR) < 1.5, APTT <1.5×control Creatinine ≤ 2.0 mg/dL Albumin ≤ trace in urine dipstick test Bilirubin ≤ 2.0 mg/dL, AST/ALT ≤ 100 IU/L
- Ligament instability ≤ Grade II
- Lower extremity alignment within 5 degrees of the neutral weight bearing axis
- No meniscal surgery within the past 3 months and more than 5mm of meniscal rim remaining
- Ability and willingness to fully participate in the post-operative rehabilitation program
- Subject is informed of the investigational nature of this study, voluntarily agrees to participate in the study, and signs an IRBapproved informed consent prior to performing any of the screening procedures
- Body Mass Index (BMI) ≤ 35 kg/m2
Exclusion Criteria:
- Patients who have been treated previously and are asymptomatic
- Avascular necrosis/ osteonecrosis
- Autoimmune or inflammatory joint disease
- History of infection within the past 6 weeks
- Surgery or radiation therapy within the past 6 weeks
- Serious medical co-morbidities, which would otherwise contraindicate surgery, as determined by the investigator
- Currently pregnant or nursing
- Psychotic diseases, epilepsy, or any history of such diseases
- Current abuse of alcohol (> 10 drinks weekly) and/or regular exposure to other substances of abuse, currently an active smoker
- Chronic inflammatory articular diseases such as rheumatoid arthritis
- Enrolled in any other clinical trials within the past 4 weeks
- Administered immunosuppressants such as Cyclosporin A or azathioprine within the past 6 weeks
- Ligament instability > Grade II
- Uncorrected significant lower extremity malalignment (i.e. > 5 degrees)
- (sub-) Total meniscectomy (<5mm rim remaining)
- Corticosteroid or viscosupplementation injection to the affected knee in the past 3 months
- Principal investigator considers inappropriate for the clinical trial due to any reasons other than those listed above
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CARTISTEM®
Drug name and ingredients: CARTISTEM [allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate] Dosage: Administer 0.5 mL of the combination product per cm^2 of the cartilage defect
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IKDC Score
Time Frame: 12 months
|
Subjects underwent a self-assessment of knee function using the IKDC (International Knee Documentation Committee Assessment)subjective knee evaluation before and after the administration of the IP. The assessment is designed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment. The possible score ranges from 0 to 100, where 100 = no limitation with daily or sporting activities and the absence of symptoms. The IKDC assessment was performed before IP administration and at Months 12 after IP administration in an exploratory fashion. The IKDC score from the Month 12 visit was used as a primary indicator of the post operative change. The outcome was presented with the post-operative change amount from the baseline. |
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VAS
Time Frame: 24 months
|
Subjects underwent a self-assessment of joint pain using the 100-mm VAS (Visual Analogue Scale) before and at Months 12 and 24 after IP (investigational product) administration. Higher values represent worse joint pain. Use of NSAIDs and any other analgesics had to be discontinued for 48 hours and 24 hours, respectively, prior to the 100 mm VAS evaluation. The outcome was presented with the post-operative change amount at Months 12 and 24 from the baseline. 100-mm VAS scores range from 0 to 100. Higher values represent worse joint pain. |
24 months
|
Lysholm Score
Time Frame: 24 months
|
The Lysholm knee scoring scale is a self-assessment that rates the severity of common complaints related to knee problems, such as pain, swelling, abnormal sensations, and ability to squat or climb stairs.
The possible score ranges from 0 to 100, where 100 = no symptoms or disability.
Scores are categorized as excellent (95 to 100), good (84 to 94), fair (65 to 83), and poor (≤64).
Subjects underwent a self-assessment of knee function using the Lysholm score before IP administration and at Months 12 and 24 after IP administration.
The outcome was presented with the post-operative change amount at Months 12 and 24 from the baseline.
|
24 months
|
KOOS Score
Time Frame: 24 months
|
The Knee Injury and Osteoarthritis Outcome score (KOOS) knee survey is a self assessment of knee function and knee-related quality of life (QOL).
Subjects responded to each question regarding knee-related symptoms, swelling, pain, impaired function, or changes in QOL with 1 of 5 possible answers that range from "never/not at all" to "always/extremely."
The possible score for each parameter ranges from 0 to 100, where 0=extreme problems and 100=no problems.
Subjects completed the KOOS knee survey before IP (investigational product) administration and at Month 24 after IP administration.
The outcome was presented with the post-operative change amount at Month 24 from the baseline.
|
24 months
|
IKDC Score
Time Frame: 24 months
|
Subjects underwent a self-assessment of knee function using the IKDC subjective knee evaluation before and after the administration of the IP.
The assessment is designed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment.
The possible score ranges from 0 to 100, where 100 = no limitation with daily or sporting activities and the absence of symptoms.
The IKDC assessment was performed before IP administration and at Month 24 after IP administration in an exploratory fashion.
The outcome was presented with the post-operative change amount at Month 24 from the baseline.
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Brian J Cole, MD, Cartilage Restoration Center, Rush University Medical Center
- Principal Investigator: Andreas H Gomoll, MD, Cartilage Repair Center, Brigham and Women's Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MP-0201-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degeneration Articular Cartilage Knee
-
Sewon Cellontech Co., Ltd.UnknownDefect of Articular Cartilage | Articular Cartilage Disorder of Knee | Degeneration; Articular Cartilage, KneeKorea, Republic of
-
Biosolution Co., Ltd.Active, not recruitingArticular Cartilage Defect | Articular Cartilage DegenerationKorea, Republic of
-
KLSMC Stem Cells, Inc.CompletedArticular Cartilage Disorder of Knee | Articular Cartilage; DegenerationUnited States, Malaysia
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationActive, not recruitingArticular Cartilage DegenerationSwitzerland
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
Biosolution Co., Ltd.RecruitingArticular Cartilage Defect | Articular Cartilage DegenerationUnited States
-
Middle East Technical UniversityCompletedOsteoarthritis | Degenerative Lesion of Articular Cartilage of Knee | Articular Cartilage Disorder of KneeTurkey
-
CellCoTec B.V.CompletedArticular Cartilage Lesion of the KneeBelgium, Poland, United Kingdom
-
Zimmer Orthobiologics, Inc.TerminatedDefect of Articular Cartilage | Articular Cartilage Disorder | Degeneration; Articular Cartilage | Chronic Cartilage Injury | Acute Cartilage InjuryUnited States
-
Episurf Medical Inc.MCRARecruitingDegenerative Lesion of Articular Cartilage of KneeUnited States, Canada, Germany, United Kingdom
Clinical Trials on CARTISTEM®
-
Hyundai Bioland Co., Ltd.Medipost Co Ltd.CompletedChondral or Osteochondral Lesion of TalusKorea, Republic of
-
Medipost Co Ltd.CompletedOsteoarthritis | Cartilage InjuryKorea, Republic of
-
Medipost Co Ltd.Dong-A Pharmaceutical Co., Ltd.CompletedDefect of Articular Cartilage | Degenerative OsteoarthritisKorea, Republic of
-
Samsung Medical CenterUnknownOsteochondral Lesion of TalusKorea, Republic of
-
Samsung Medical CenterCompletedDeficiency of Anterior Cruciate LigamentKorea, Republic of
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompleted
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Amir AzarpazhoohInstitut Straumann AGCompletedPeriodontal Inflammation | Crown LengtheningCanada
-
Novartis PharmaceuticalsCompletedPulmonary Disease, Chronic Obstructive (COPD)Argentina